| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | colesevelam (Cholestagel®) |
| Formulation | 625 mg film-coated tablet |
| Reference number | 95 |
| Indication | Co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) as adjunctive therapy to diet to provide an additive reduction in low-density lipoprotein cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Monotherapy as adjunctive therapy to diet for reduction of elevated total-cholesterol and LDL-C in adult patients with isolated primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated |
| Company | Genzyme Therapeutics |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 12/12/2007 |